|
Corporate Presentation |
|
Seladelpar Improved the Lipid Profile of Patients With Primary Biliary Cholangitis (PBC): Results From Phase 2 and 3 Clinical Studies |
|
Seladelpar, a PPAR-delta agonist, improves inflammatory lipid mediators in the serum metabolome in patients with primary biliary cholangitis (PBC) |
|
Effects of single and multiple doses of the selective PPARĪ“ agonist seladelpar on diurnal markers of bile acid synthesis in mice |
|
The selective PPAR-delta agonist seladelpar (MBX-8025) suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway |
